Valeant Pharmaceuticals International, Inc. (TSE:VRX) (NYSE:VRX)‘s stock had its “sector perform” rating reaffirmed by stock analysts at Royal Bank Of Canada in a report released on Wednesday, November 8th, StockTargetPrices.com reports. They presently have a C$23.00 price target on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s target price would suggest a potential upside of 22.34% from the company’s previous close.
Separately, TD Securities increased their target price on Valeant Pharmaceuticals International to C$26.00 and gave the company a “hold” rating in a research report on Wednesday, July 12th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Valeant Pharmaceuticals International currently has a consensus rating of “Hold” and an average target price of C$22.50.
Shares of Valeant Pharmaceuticals International (TSE VRX) traded up C$0.52 during trading hours on Wednesday, reaching C$18.80. The company had a trading volume of 1,068,200 shares, compared to its average volume of 1,430,540. Valeant Pharmaceuticals International has a 52 week low of C$11.20 and a 52 week high of C$25.22.
In other news, Director Schutter Richard Urbain De bought 4,900 shares of Valeant Pharmaceuticals International stock in a transaction that occurred on Monday, August 21st. The stock was bought at an average price of C$14.35 per share, for a total transaction of C$70,315.00.
About Valeant Pharmaceuticals International
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.